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Abstract
Background Dimethyl fumarate (DMF) is an oral drug approved for Relapsing Multiple Sclerosis (RMS) patients. Grade III 
lymphopenia is reported in 5–10% DMF-treated patients. Data on lymphocyte count (ALC) recovery after DMF withdrawal 
following prolonged lymphopenia are still scarce.
Objectives To characterize ALC recovery and to identify predictors of slower recovery after DMF interruption.
Methods Multicenter data from RMS patients who started DMF and developed lymphopenia during treatment were col-
lected. In patients with grade II–III lymphopenia, ALCs were evaluated from DMF withdrawal until reaching lymphocyte 
counts > 800/mm3.
Results Among 1034 patients who started DMF, we found 198 (19.1%) patients with lymphopenia and 65 patients (6.3%) 
who discontinued DMF due to persistent grade II–III lymphopenia. Complete data were available for 51 patients. All patients 
recovered to ALC > 800 cells/mm3 with a median time of 3.4 months. Lower ALCs at DMF suspension (HR 0.98; p = 0.005), 
longer disease duration (HR 1.29; p = 0.014) and prior exposure to MS treatments (HR 0.03; p = 0.025) were found predic-
tive of delayed ALC recovery.
Conclusion ALC recovery after DMF withdrawal is usually rapid, nevertheless it may require longer time in patients with 
lower ALC count at DMF interruption, longer disease duration and previous exposure to MS treatments, potentially leading 
to delayed initiation of a new therapy.
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Introduction
Several injectable, oral, and infusible Disease-Modifying 
Drugs (DMDs) approved for the treatment of Relapsing 
Multiple Sclerosis (RMS) can result in a decrease of abso-
lute lymphocyte count (ALC) with different mechanism 
of action [1]. Lymphopenia is defined as a decrease in 
number of lymphocytes under lower limit normal (LLN) 
for a specific laboratory, and can be classified from grade 
I to IV following ALC value [2]. Clinicians need to care-
fully monitor ALC in patients treated with DMDs because 
lymphopenia can be associated with an increased risk of 
opportunistic infection [1].
Dimethyl fumarate (DMF) is an oral drug who demon-
strated a class I evidence of efficacy for RMS patients in 
terms of annualized relapse rate (ARR) and radiological 
activity in two independent randomized clinical trials [3, 
4].
In clinical trials, a reduction in ALC of approximately 
30% within 1 year of treatment was reported and about 
4–5% of patients reported a grade III lymphopenia [5]. 
DMF does not affect all lymphocyte subsets uniformly. 
CD8 + T cells are the most profoundly affected and CD4 +, 
B-lymphocyte, myeloid, and natural killer populations are 
also shifted toward a more anti-inflammatory state [6].
Recently, DMF-associated lymphopenia has gained clini-
cians’ interest due to few reports of Progressive Multifocal 
leukoencephalopathy (PML) in RMS patients treated with 
MS following prolonged lymphopenia [7–9]. Lymphopenia 
incidence rate in post-marketing studies is extremely vari-
able, ranging from 10 to 30%, and even grade III lympho-
penia is variable from 2.5 to 11% [10–12]. Advanced age, 
lower baseline ALC and female sex seem to increase the risk 
of DMF-induced lymphopenia [10, 13]. There was no strict 
indications in the management of DMF-induced lympho-
penia from regulatory authorities. As for EMA prescribing 
information, ALC is required before starting DMF and every 
3 months during treatment. DMF should be interrupted in 
patients with lymphocyte counts < 500/mm3 persisting for 
more than 6 months and the benefit/risk in patients with 
lymphocyte counts ≥ 500/mm3 and < 800/mm3 for more than 
6 months should be assessed [14].
FDA prescribing information suggest obtaining ALC 
every 6 months after starting treatment and considering the 
interruption of DMF in patients with lymphocyte counts less 
than 0.5 × 109/L persisting for more than 6 months [15].
These statements stress the need of strict ALC monitor-
ing but leave the clinician different possible interpretation 
in timing of DMF interruption. DMF prescribing informa-
tion form recommends ALC monitoring during treatment 
and after DMF discontinuation because of lymphopenia 
until ALC normalization.
Only two studies investigated the features of lymphocyte 
count recovery after DMF-induced lymphopenia and evi-
dence is still scarce. One study analyzed ALC data of the 
patients included in ENDORSE study (extension study of 
DMF RCTs) and the other was a monocentric study that 
evaluated data of 11 patients who discontinued DMF follow-
ing prolonged grade III lymphopenia [16, 17].
This multicentric study aims to characterize the tempo-
ral dynamic of ALC recovery and to identify predictors of 




This was an independent, multi-center, retrospective, post-
marketing, observational study. We retrospectively analyzed 
data of patients affected by RMS [18] regularly attending 
seven tertiary MS outpatient clinics in Central Italy (Fon-
dazione Policlinico ’A. Gemelli’ IRCCS, S. Andrea Hospi-
tal, S. Camillo-Forlanini Hospital, Policlinico Umberto I, 
Policlinico Tor Vergata, S. Filippo Neri Hospital, Rome and 
IRCCS Neuromed, Pozzilli) who started DMF from October 
2012 to December 2017. Clinical, laboratory and MRI data 
were collected by each MS center, following the local DMF 
monitoring plan and hospital guidelines.
Participants
We collected data of patients with RMS who started DMF 
as first treatment (naïves) or were switched from other dis-
ease modifying drugs (DMDs). We excluded patients who 
received the first treatment prescription by one MS center 
but were lost at follow-up.
At baseline, we recorded the following clinical and 
demographical variables: sex, age, time since first symp-
tom, EDSS score, relapses in the year before starting DMF, 
absence/presence of Gd + lesions, previous treatment history 
to classify patients in naïve or switchers.
ALC monitoring
Lymphopenia was classified according to the common ter-
minology criteria used for adverse events definition [2]. An 
ALC lower than LLN but higher than 800/mm3 defines a 
grade I lymphopenia, an ALC between 500 and 800/mm3 
grade II lymphopenia, an ALC between 200 and 500/mm3 
grade III and an ALC under 200/mm3 grade IV lymphope-
nia. Time interval between DMF start and first observation 
of lymphopenia was calculated.
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ALCs longitudinal data of patients with grade II–III 
lymphopenia were collected from DMF withdrawal until 
reaching lymphocyte counts > 800/mm3. Mean time inter-
val between DMF interruption and ALC normalization was 
calculated. We excluded patients with incomplete data (less 
than three ALC counts unless ALC count normalized within 
60 days from DMF withdrawal) or who started a new DMD 
before reaching an ALC > 800/mm3.
Statistical analysis
Continuous variables were described as mean ± standard 
deviation unless otherwise specified. Dichotomic or cate-
gorial variables were expressed as frequencies. Differences 
between lymphopenic and non-lymphopenic patients were 
explored with t test for independent groups and Chi-squared 
test as appropriate.
Cox proportional hazards model (stratified by Centre) 
was carried out to investigate which baseline (i.e., at treat-
ment start) variables were associated with the development 
of lymphopenia during treatment with DMF. We evaluated 
predictors of slower ALC recovery (longer than 4 months) 
through a Binary Logistic Regression model.
All two-tailed p values < 0.05 were considered as signifi-
cant, without correction for multiple comparisons consider-
ing the exploratory study design. Data were analyzed using 
the Statistical Package for Social Sciences, version 16.0 
(IBM SPSS, Inc., Chicago, Ill., USA).
Results
Participants
We evaluated clinical data of 1034 MS patients. Base-
line demographic and clinical characteristics of whole 
study population are described in Table  1. After a 
median follow-up of 34 months, 198 (19.1%) developed 
lymphopenia; 51 (4.9%), 87 (8.4%), and 60 (5.8%) 
patients, respectively, had grade I, II and III lymphopenia 
(14.2% grade II and III combined). Mean time to onset of 
lymphopenia was 11.3 ± 7.5 months.
Older age (HR 1.03; 95% CIs 1.02–1.05; p < 0.001) and 
female sex (HR 1.55; 95% CIs 1.10–2.18; p = 0.012) were 
significant independent baseline predictors of lymphopenia 
development during DMF treatment (Table 2) through Cox 
regression analysis.
Lymphocyte count recovery
Sixty-five patients (6.3%) discontinued DMF with persis-
tent grade II or III lymphopenia. Fourteen patients were 
excluded because incomplete data or loss at follow-up after 
DMF discontinuation.
We evaluated ALCs of 51 patients from DMF withdrawal 
until reaching lymphocyte counts > 800/μl. (Fig. 1).
Mean age was 45.9 years with a female predominance 
(86.3%) and a median EDSS score of 2.0 (range 0.0–6.0). 
Mean disease duration was 10.9 ± 8.8  years and mean 
Table 1  Whole patient cohort and lymphopenic vs non-lymphopenic patients
EDSS Expanded Disability Status Score, ALC Absolute lymphocyte count, Gd + gadolinium-enhancing lesion
All values are reported as mean (standard deviation) unless indicated otherwise
In bold are reported significant difference at a two-sided α level < 0.05
Patients Whole cohort (n = 1034) Normal ALC (n = 836) Lymphopenia = 198 p value
Female sex [n (%)] 723 (69.9) 569 (68.1) 154 (77.8) 0.007
Age, years 38.8 (10.2) 38.0 (10.1) 42.1 (10.1)  < 0.001
Time since first symptom, years 9.5 (8.0) 9.4 (7.9) 9.9 (8.2) 0.407
EDSS score 1.94 (1.5) 1.94 (1.5) 1.92 (1.4) 0.862
Treatment naïves [n (%)] 318 (30.8%) 263 (31.5) 55 (27.8) 0.313
No. of relapses in previous year 0.56 (0.7) 0.54 (0.7) 0.61 (0.8) 0.218
No. of Gd + lesions 0.68 (1.3) 0.67 (1.2) 0.73 (1.4) 0.542
Table 2  Cox regression models (stratified by MS center) to develop 
lymphopenia during DMF treatment
MS multiple sclerosis, DMF dimethyl fumarate, HR hazard ratio, 
95% CIs 95% confidence intervals, EDSS Expanded Disability Status 
Score
In bold are reported significant difference at a two-sided α level < 0.05
Patients n = 1134
HR 95% CIs p value
Age (each year) 1.03 1.02–1.05  < 0.001
Disease duration (each 
year)
0.99 0.97–1.01 0.484
Female sex 1.55 1.10–2.18 0.012
EDSS 1.02 0.92–1.14 0.655
Naïves 1.34 0.94–1.91 0.103
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follow-up on DMF was 22.3 ± 11.9  months. Nineteen 
patients (37.2%) were naïve to treatment, while 32 (62.8%) 
were switched from another treatment; in 3 cases, the 
previous treatment was fingolimod and in 1 case, natali-
zumab (Table 3).
All patients recovered ALC to at least > 800 cells/mm3 
during follow-up in a median time interval of 3.4 months 
(mean 4.2 and interquartile range 1.4–6.1) (Fig. 2).
Twenty-eight patients (55%) recovered from lym-
phopenia within 3 months after DMF withdrawal and 40 
patients (78%) within 6 months. Two patients had a very 
delayed recovery lasting over a year (respectively, 12.6 and 
13.7 months).
Predictors of lymphocyte count recovery
We divided patients into two groups based on the duration 
of lymphopenia after DMF discontinuation and we used 4 
months as cutoff to define a delayed ALC recovery. Twenty 
patients (39.2%) of patients have an ALC recovery longer 
than 4 months. Through a binary logistic regression analysis, 
we found that lower ALC at DMF suspension (HR 0.99; 
95% CIs 0.98–0.99; p = 0.008), longer disease duration (HR 
1.13; 95% CIs 1.01–1.27; p = 0.031) and prior exposure to 
MS treatments (HR 0.08; 95% CIs 0.01–0.54; p = 0.01) were 
significant predictors of slower ALC recovery (Table 4).
We cannot evaluate the impact of every single previous 
DMT exposure considering the low number of patients for 
each treatment. Notably, the two patients switching from 
fingolimod and developing grade III lymphopenia had both 
a slow recovery lasting more than 6 months (respectively, 
6.1 and 7.5 months) but potential confounding interaction 
Fig. 1  Study flow-chart
Table 3  Baseline characteristics 
of patients who discontinued 
DMF with grade II–III 
lymphopenia
DMF dimethyl fumarate, EDSS Expanded Disability Status Score, DMD disease modifying drug
All values are reported as mean (standard deviation) unless indicated otherwise
Patients Grade II–III lymphope-
nia (n = 51)





Female sex [n (%)] 44 (86.3) 21 (91.3) 23 (82.1)
Age, years 45.9 (10.7) 44.4 (11.6) 47.1 (10.1)
Time since first symptom, years 10.9 (8.8) 9.7 (8.4) 11.9 (9.0)
EDSS score, median [range] 2.0 [0.0–6.0] 2.0 [0.0–6.0] 2.0 [0.0–6.0]
Treatment naïves [n (%)] 19 (37.2) 9 (39.1) 10 (35.7)
Prior DMDs [n (%)]
 Glatiramer acetate [n (%)]
 Interferon beta 1 a [n (%)]


























Follow-up in months on DMF 22.3 (± 11.9) 23.0 (± 12.1) 21.7 (± 11.8)
Lymphopenia duration before DMF 
withdrawal (months)
11.2 (± 9.7) 11.2 (± 8.7) 11.2 (± 10.6)
Time to lymphocyte count recovery 
(months), median [range]
3.4 [0.3–13.7] 2.5 [0.3–8.4] 5.2 [0.5–13.7]
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of age (> 50 year) and disease duration (> 10 years) cannot 
be excluded.
Discussion
Several DMDs can lead to a variable degree of ALC reduc-
tion following different mechanism of action. Development 
of selective lymphopenia may even reflect treatment effects 
as part of the drug mechanism of action for several DMDs 
such as alemtuzumab, cladribine, ocrelizumab and fingoli-
mod that share depleting/sequestrating mechanism of action 
[1].
DMF is associated with an ALC reduction within 1 year 
of treatment and modifies lymphocyte subset causing a 
higher reduction of CD19 + B cells and CD8 + T cells with 
an increase in CD4 + /CD8 + ratio. DMF not only alters ALC 
quantitatively but also qualitatively with a reduction of T 
and B memory cells and an expansion of T and B naïve cells 
[16, 19–22]
In our study, we found an incidence of 14.2% for grade 
II and III lymphopenia combined in over 1000 MS patients 
treated with DMF for nearly 3 years. As previously pub-
lished by our group, we confirmed that older age and female 
sex are associated with higher risk of developing lymphope-
nia during DMF treatment [10].
Our data are consistent to RCTs and ENDORSE study as 
lymphopenia incidence was about 4–5% for grade III lym-
phopenia and near 12% for grade II and III combined [3, 4, 
23].
Although there are few reports of PML in severe lympho-
penic DMF-treated patients, lymphopenia was not associated 
with a higher risk of severe infection [7, 16, 23].
In post-marketing studies, wide variability in lymphope-
nia incidence rate was reported ranging from 10 to 30%, 
with grade III lymphopenia ranging from 2 to 10%. Different 
DMF exposure duration and demographic and clinical fea-
tures (age at DMF initiation; previous exposure to DMDs) 
can explain such variability. The association between lym-
phopenia and patient’s age was, however, consistent in those 
studies [11, 12, 24, 25].
A recent paper from Sabin et al. found a 30% incidence 
rate for lymphopenia with 6% of grade III lymphopenia 
[26]. Their cohort was comparable to ours in terms of DMF 
exposure duration (3 years), naïve/switchers ratio (near 30% 
of naïve patients) and mean age (near 40 years). Our study 
shows a comparable rate of grade III lymphopenia while 
we found a lower incidence of lymphopenia including all 
grades. Difference among laboratories in the reference val-
ues defining lower normal lymphocyte limit may account for 
variability in grade I lymphopenia diagnosis [26].
While RCTs and real-world studies explored the inci-
dence of lymphopenia during DMF treatment and the pres-
ence of potential predictors of this side effects, data regard-
ing the restoration of ALC after DMF discontinuation for 
prolonged lymphopenia are still scarce.
In our study, we evaluated ALCs after DMF withdrawal 
of 51 patients with prolonged grade II–III lymphopenia (29 
with grade III lymphopenia). Despite there are no current 
data regarding the level of ALC considered safe to start a 
new therapy, we chose a level of lymphocyte greater than 
800 cells/mm3 to define an ALC restoration. All patients 
recovered to ALC > 800 cells/mm3 with a median time of 
3.4 months. The time of ALC recovery was widely variable 
with eleven patients that recovered after more than 6 months, 
and two patients that recovered after more than a year.
Mehta et al. evaluated ALC data of patients included in 
ENDORSE study. They identified 207 patients with at least 
one ALC < 800 cells/mm3 (they excluded from this analysis 
Fig. 2  Lymphocyte count recovery after DMF withdrawal. Lympho-
cyte count recovery after DMF withdrawal. Each line represents the 
trend of lymphocyte count for a single patient. The horizontal line 
represents the cutoff for grade I lymphopenia (800 cells/mm3). ALC 
absolute lymphocyte count, DMF dimethyl fumarate
Table 4  Binary Logistic Regression model to evaluate predictors of 
lymphopenia-delayed recovery (longer than 4 months).
HR hazard ratio, 95% CIs 95% confidence intervals, DMF dimethyl 
fumarate, EDSS Expanded Disability Status Score
In bold are reported significant difference at a two-sided α level < 
0.05
Patients n=51
HR 95% CIs P
Lymphocyte count at DMF suspension 0.99 0.98-0.99 0.008
Age (each year) 0.94 0.87-1.02 0.156
Disease duration (each year) 1.13 1.01-1.27 0.031
Female sex 0.49 0.17-1.39 0.180
EDSS 1.21 0.71-2.05 0.492
Naïves 0.08 0.01-0.54 0.010
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patients with persistent grade III lymphopenia) and they 
found that ALC recovered to at least 800 cells/mm3 in 82% 
of patients with 63% within 4–5 weeks from DMF suspen-
sion. In this large cohort, they found 49 patients with pro-
longed ALC < 500 cells/mm3, but they have complete data 
only for 15 patients. In this subgroup, they found that near 
40% of patients recovered to ALC > 800 within a median 
time of 35 weeks [16].
A monocentric study from Switzerland identified 11 
patients (4.5% of their cohort) who discontinued DMF fol-
lowing prolonged grade III lymphopenia. Six patients were 
treatment naïve before starting DMF, and no one received 
prior treatment with cell-depleting immunotherapies (4 
IFNβ-1a and 1 natalizumab). They found that ALC raised 
to at least 800 cells/mm3 in all patients within 6 months and 
with a median time of 2 months. They also identified age at 
withdrawal of DMF as an independent predictor for a longer 
duration of lymphocyte repopulation [17].
Looking at predictors of slower recovery, we found that 
longer disease duration and prior exposure to MS treatments 
were associated with longer time to ALC recovery.
Study limits
Although our study includes clinical and laboratory data 
from patients attending MS tertiary outpatient clinics, we 
cannot rule out bias due to the retrospective study design 
from clinical practice. In fact, we cannot exclude a certain 
variability of the frequencies of ALC counts execution after 
DMF suspension. By excluding patients with less than three 
ALC counts (unless ALC count normalized within 60 days 
from DMF withdrawal), we have tried to minimize these 
potential data discrepancies.
Conclusion
The development of lymphopenia is a critical issue not only 
during DMF treatment but also after its withdrawal. There 
is no specific wash-out period duration before starting a new 
DMD after DMF suspension and there are no studies who 
evaluated an eventual additional immunosuppressive effect 
of a new DMD before complete ALC restoration.
Despite ALC recovery is rapid in most cases, we high-
lighted that some patients, especially with longer disease 
duration and previous exposure to DMDs, can have a very 
slow recovery of lymphocyte count after DMF suspension 
with consequent impact in the initiation of a new DMD. 
In such cases, the clinician needs to carefully evaluate the 
risk–benefit ratio for each single patient to avoid disease 
activity and to reduce the potential risk (not explored) of an 
additional immunosuppressive effect.
Although in the majority of patients even a prolonged 
ALC reduction during DMF treatment may not be “per se” 
significantly immunosuppressive, further studies will be 
necessary to evaluate whether ALC recovery after lympho-
penia related DMF suspension may correlate with specific 
previous treatments and individual patient characteristics 
possibly helping clinicians in better DMD sequencing.
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